[Cardiac stem and progenitor cell therapy: ready for the future?]

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Biomedical Engineering

Background:

• Cardiovascular diseases are a leading cause of mortality globally.
• Regenerative medicine offers potential for myocardial repair post-infarction or cardiomyopathy.
• Current cell-based therapies show marginal clinical benefits, with only a 3% average improvement in cardiac function.

Purpose of the Study:

• To review the challenges and future directions in cell-based myocardial regenerative therapies.
• To identify key unanswered questions hindering clinical translation.
• To explore novel regenerative strategies beyond traditional stem cell approaches.

Main Methods:

• Analysis of existing literature and meta-analyses on cell-based cardiac therapies.
• Identification of critical factors for effective clinical translation, including cell type, delivery, timing, and application format.
• Review of advanced imaging and animal models for therapy assessment.
• Exploration of induced pluripotent stem cells (iPSCs) and direct reprogramming techniques.

Main Results:

• Clinical translation of cell-based therapies for cardiac repair has shown limited efficacy.
• Significant knowledge gaps exist regarding optimal cell selection, delivery methods, timing, and outcome measures.
• Advanced imaging and validated animal models are crucial for assessing therapy effectiveness.
• Direct reprogramming of fibroblasts to cardiomyocytes presents a potential new regenerative strategy.

Conclusions:

• Optimizing cell-based therapies is essential for achieving long-term cardiac regeneration and improving clinical outcomes.
• Further research into novel approaches like induced pluripotent stem cells and direct reprogramming is warranted.
• Addressing key translational challenges is critical for realizing the full potential of regenerative medicine in cardiology.